PMN

Company Overview — What Does ProMIS Neurosciences Inc. Do?

N/A ProMIS Neurosciences Inc. (PMN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Gail M. Farfel and employs approximately 5 people. With a market capitalization of $117M, PMN is one of the notable companies in the Healthcare sector.

ProMIS Neurosciences Inc. (PMN) Stock Rating — Reduce (April 2026)

As of April 2026, ProMIS Neurosciences Inc. receives a Reduce rating with a composite score of 31.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PMN ranks #3,525 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ProMIS Neurosciences Inc. ranks #553 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PMN Stock Price and 52-Week Range

ProMIS Neurosciences Inc. (PMN) currently trades at $12.60. The stock gained $0.10 (0.8%) in the most recent trading session. The 52-week high for PMN is $27.40, which means the stock is currently trading -54.0% from its annual peak. The 52-week low is $0.29, putting the stock 4278.0% above its annual trough. Recent trading volume was 36K shares, suggesting relatively thin trading activity.

Is PMN Overvalued or Undervalued? — Valuation Analysis

ProMIS Neurosciences Inc. (PMN) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.12x, versus the sector average of 2.75x.

At current multiples, ProMIS Neurosciences Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ProMIS Neurosciences Inc. Profitability — ROE, Margins, and Quality Score

ProMIS Neurosciences Inc. (PMN) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -215.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -215.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PMN Debt, Balance Sheet, and Financial Health

ProMIS Neurosciences Inc. has a debt-to-equity ratio of 134.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 0.88x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $0. Cash and equivalents stand at $15M.

PMN has a beta of 3.34, meaning it is more volatile than the broader market — a $10,000 investment in PMN would be expected to move 234.2% more than the S&P 500 on any given day. The stability factor score for ProMIS Neurosciences Inc. is 8/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ProMIS Neurosciences Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ProMIS Neurosciences Inc. reported revenue of $0 and earnings per share (EPS) of $-22.61. Net income for the quarter was $-20M. Operating income came in at $-34M.

In FY 2025, ProMIS Neurosciences Inc. reported revenue of $0 and earnings per share (EPS) of $-22.61. Net income for the quarter was $-40M. Operating income came in at $-40M.

In Q3 2025, ProMIS Neurosciences Inc. reported revenue of $0 and earnings per share (EPS) of $-0.24. Net income for the quarter was $-12M. Operating income came in at $-12M.

In Q2 2025, ProMIS Neurosciences Inc. reported revenue of $0 and earnings per share (EPS) of $-0.29. Net income for the quarter was $-10M. Operating income came in at $-10M.

Over the past 8 quarters, ProMIS Neurosciences Inc. has experienced revenue contraction from $0 to $0. Investors analyzing PMN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PMN Dividend Yield and Income Analysis

ProMIS Neurosciences Inc. (PMN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PMN Momentum and Technical Analysis Profile

ProMIS Neurosciences Inc. (PMN) has a momentum factor score of 80/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 29/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

PMN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ProMIS Neurosciences Inc. (PMN) ranks #553 out of 838 stocks based on the Blank Capital composite score. This places PMN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PMN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PMN vs S&P 500 (SPY) comparison to assess how ProMIS Neurosciences Inc. stacks up against the broader market across all factor dimensions.

PMN Next Earnings Date

No upcoming earnings date has been announced for ProMIS Neurosciences Inc. (PMN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PMN? — Investment Thesis Summary

The quantitative profile for ProMIS Neurosciences Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. Price momentum is positive at 80/100, suggesting the trend favors buyers. High volatility (stability score 8/100) increases portfolio risk.

In summary, ProMIS Neurosciences Inc. (PMN) earns a Reduce rating with a composite score of 31.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PMN stock.

Related Resources for PMN Investors

Explore more research and tools: PMN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PMN head-to-head with peers: PMN vs AZN, PMN vs SLGL, PMN vs VMD.